rethinkTHC Search
Menu
Study breakdown

Endocannabinoid drugs reduced anxiety but did not erase fear memories in a rat PTSD model

Animal StudyPreliminary evidence
The takeaway

In rats with extinction-resistant fear (modeling PTSD), a CB1 agonist reduced anxiety-like behavior, but neither it nor an endocannabinoid-boosting drug altered the expression of conditioned fear memories.

PTSD researchers, neuroscientists studying fear circuits, and clinicians interested in cannabinoid-based anxiety treatments.

CB1 agonist reduced anxiety but did not alter fear recall

What the researchers found

Acute WIN55,212-2 (CB1 agonist) reduced anxiety in "weak extinction" rats but did not affect fear recall. The FAAH inhibitor URB597 did not reduce anxiety or fear acutely. The CB1 inverse agonist AM251 increased anxiety in normal-extinction rats. Chronic administration of neither URB597 nor AM251 altered fear or anxiety, and did not change FAAH or CB1 expression.

Why it matters

PTSD involves both anxiety and persistent fear memories. This study suggests the endocannabinoid system may help with PTSD-related anxiety but may not be sufficient to eliminate extinction-resistant fear memories.

The numbers in context

25-30% of rats showed weak extinction (modeling PTSD). WIN55,212-2 reduced anxiety in WE rats. AM251 increased anxiety in SE rats. No drug condition altered freezing during fear recall.

How the study worked

Rats underwent fear conditioning and were segregated into weak extinction (WE, modeling PTSD) and strong extinction (SE) groups. Acute and chronic endocannabinoid-modulating drugs were tested on fear recall and novelty-suppressed feeding (anxiety measure).

What this study cannot tell us

Animal model may not fully capture human PTSD complexity. Systemic drug administration does not target specific brain regions. Only one dose of each drug was tested. Fear recall was measured by freezing, which may not capture all aspects of fear response.

How to read the evidence

Controlled preclinical study with relevant behavioral paradigm, but systemic drug delivery and single-dose testing limit conclusions.

When this study was published

2020 animal study. Helps clarify which PTSD symptoms might respond to endocannabinoid modulation.

The bigger picture

The distinction between anxiety and fear memory is important for PTSD treatment. Endocannabinoid-based therapies might address generalized anxiety in PTSD without necessarily helping with the core trauma memories.

Questions still open

  • Would targeted brain-region delivery of endocannabinoid drugs be more effective for fear extinction? Could combining endocannabinoid therapy with exposure therapy improve outcomes? Do different cannabinoid compounds have different effects on fear vs. anxiety?

Common questions

What are weak extinction rats?
About 25-30% of rats that undergo fear conditioning fail to learn that the fear cue is no longer dangerous. These "weak extinction" rats model the extinction-resistant fear seen in PTSD.
Why did the CB1 agonist help anxiety but not fear?
Anxiety and conditioned fear involve overlapping but distinct brain circuits. The endocannabinoid system may regulate generalized anxiety more readily than deeply encoded associative fear memories.

Read the original research

Endocannabinoid modulating drugs improve anxiety but not the expression of conditioned fear in a rodent model of post-traumatic stress disorder.

Neuropharmacology, 166, 107965

Citation

Vimalanathan, Akshayan; Gidyk, Darryl C; Diwan, Mustansir; Gouveia, Flavia V; Lipsman, Nir; Giacobbe, Peter; Nobrega, José N; Hamani, Clement. (2020). Endocannabinoid modulating drugs improve anxiety but not the expression of conditioned fear in a rodent model of post-traumatic stress disorder.. Neuropharmacology, 166, 107965. https://doi.org/10.1016/j.neuropharm.2020.107965

Explore the wider topic